EMA Authorised: Trodelvy (sacituzumab govitecan) — Gilead Sciences Ireland UC

View source ↗

Summary

EMA authorised Trodelvy (sacituzumab govitecan) for breast neoplasms, including triple negative breast neoplasms, with Gilead Sciences Ireland UC as the MAH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Triple Negative Breast Neoplasms

Drugs mentioned

• TRODELVY (sacituzumab govitecan)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms;Triple Negative Breast Neoplasms. MAH: Gilead Sciences Ireland UC. Decision date: 22/06/2026